title: Regression of prostate cancer following administration of Genistein Combined Polysaccharide (GCP), a nutritional supplement: a case report.
abstract: OBJECTIVE
  It has been reported that genistein, an isoflavone used in soybeans, has antiprostate cancer effects. Genistein Combined Polysaccharide (GCP trade mark; AMino Up, Sapporo, Japan), a nutritional supplement manufactured in Japan, is composed of genistein and a polysaccharide obtained from basidiomycetes (mycelia) that grows in a variety of mushrooms.
  
  
  METHODS
  We report a case of a patient with a biopsy proven prostate cancer showing clinical and pathologic evidence of regression following administration of GCP. The patient was enrolled in an Institutional Review Board (IRB)-approved protocol and received GCP for 6 weeks prior to radical prostatectomy.
  
  
  RESULTS
  The patient's prostate-specific antigen (PSA) decreased from an initial value of 19.7 to 4.2 ng/mL after 44 days of low-dose GCP. No cancer was identified in the radical prostatectomy specimen and no side effects were observed in this patient.
  
  
  CONCLUSIONS
  This case suggests that GCP, which has shown potent inhibitory effects against prostate cancer in vitro, may have some potential activity in the treatment and prevention of prostate cancer.
authors.affiliation: Department of Urology, College of Physicians and Surgeons of Columbia University, New York, NY, USA.
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Ghafar
authors.forename: Erica
authors.initials: E
authors.lastname: Golliday
authors.forename: Jonathan
authors.initials: J
authors.lastname: Bingham
authors.forename: Mahesh M
authors.initials: MM
authors.lastname: Mansukhani
authors.forename: Aristotelis Georgios
authors.initials: AG
authors.lastname: Anastasiadis
authors.forename: Aaron E
authors.initials: AE
authors.lastname: Katz
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001487:Basidiomycota; D014408:Biomarkers, Tumor / Q000097:blood; D004305:Dose-Response Relationship, Drug; D019833:Genistein / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D020074:Lentinula; D008297:Male; D008875:Middle Aged; D025282:Mycelium; D011134:Polysaccharides / Q000627:therapeutic use*; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D020940:Reishi; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011134:Polysaccharides; D019833:Genistein; D017430:Prostate-Specific Antigen